Sven Wind

2.8k total citations · 1 hit paper
39 papers, 2.1k citations indexed

About

Sven Wind is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Sven Wind has authored 39 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 7 papers in Genetics. Recurrent topics in Sven Wind's work include Lung Cancer Treatments and Mutations (16 papers), HER2/EGFR in Cancer Research (14 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Sven Wind is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), HER2/EGFR in Cancer Research (14 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Sven Wind collaborates with scholars based in Germany, United States and Canada. Sven Wind's co-authors include Harald Schmidt, Eduardo Barbosa‐Sicard, Katrin Schröder, Rudi Busse, Ralf P. Brandes, Peter Stopfer, Matthias Freiwald, Thomas Ebner, Knut Beuerlein and Kirstin Wingler and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Sven Wind

39 papers receiving 2.1k citations

Hit Papers

Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases b... 2007 2026 2013 2019 2007 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant
    2007 637 citations Sven Wind, Eduardo Barbosa‐Sicard et al. Hypertension profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sven Wind Germany 18 632 620 616 541 462 39 2.1k
Mukut Sharma United States 35 439 0.7× 1.1k 1.7× 204 0.3× 344 0.6× 583 1.3× 114 3.9k
Xavier Durando France 31 480 0.8× 886 1.4× 1.0k 1.7× 259 0.5× 152 0.3× 140 2.9k
Tohru Yamamori Japan 26 231 0.4× 1.4k 2.3× 252 0.4× 640 1.2× 320 0.7× 58 2.8k
Ying Shen China 30 336 0.5× 1.0k 1.7× 295 0.5× 145 0.3× 228 0.5× 129 2.4k
Robert L. Wolfert United States 34 1.4k 2.1× 1.7k 2.7× 522 0.8× 1.4k 2.6× 328 0.7× 55 4.6k
Han Si United States 21 424 0.7× 1.4k 2.3× 449 0.7× 513 0.9× 196 0.4× 55 2.7k
Iain R. Hutcheson United Kingdom 30 429 0.7× 1.4k 2.3× 1.3k 2.1× 626 1.2× 128 0.3× 50 3.2k
Frank Weinberg United States 19 320 0.5× 2.1k 3.4× 540 0.9× 228 0.4× 270 0.6× 46 3.3k
Ding Ai China 29 329 0.5× 1.5k 2.4× 170 0.3× 391 0.7× 484 1.0× 84 3.6k
Shixia Huang United States 30 372 0.6× 2.4k 3.8× 1.3k 2.2× 246 0.5× 270 0.6× 70 3.7k

Countries citing papers authored by Sven Wind

Since Specialization
Citations

This map shows the geographic impact of Sven Wind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Wind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Wind more than expected).

Fields of papers citing papers by Sven Wind

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Wind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Wind. The network helps show where Sven Wind may publish in the future.

Co-authorship network of co-authors of Sven Wind

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Wind. A scholar is included among the top collaborators of Sven Wind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Wind. Sven Wind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roessner, Philipp M., et al.. (2024). The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 45(2). 94–103. 2 indexed citations
2.
Desch, Michael, Glen Wunderlich, Karl‐Heinz Liesenfeld, et al.. (2021). Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics. 47(1). 91–103. 6 indexed citations
3.
Wind, Sven, Ulrike Schmid, Matthias Freiwald, et al.. (2019). Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clinical Pharmacokinetics. 58(9). 1131–1147. 138 indexed citations
4.
Rosenbrock, Holger, Michael Desch, Oliver Kleiner, et al.. (2018). Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies. Clinical and Translational Science. 11(6). 616–623. 33 indexed citations
5.
Moschetti, Viktoria, Michael Desch, Karl‐Heinz Liesenfeld, et al.. (2017). Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study. European Journal of Drug Metabolism and Pharmacokinetics. 43(2). 239–249. 28 indexed citations
6.
Wiebe, Sabrina, David Schnell, Dietmar Ganßer, et al.. (2016). Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study. European Journal of Drug Metabolism and Pharmacokinetics. 42(3). 461–469. 17 indexed citations
7.
8.
Wind, Sven, David Schnell, Thomas Ebner, Matthias Freiwald, & Peter Stopfer. (2016). Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clinical Pharmacokinetics. 56(3). 235–250. 146 indexed citations
9.
Passaro, Antonio, Myung‐Ju Ahn, Balázs Halmos, et al.. (2015). Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). Annals of Oncology. 26. vi77–vi77. 3 indexed citations
10.
Schnell, David, Holger Fuchs, Dietmar Ganßer, et al.. (2014). Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemotherapy and Pharmacology. 74(2). 267–275. 32 indexed citations
11.
Reardon, David A., Burt Nabors, Warren Mason, et al.. (2014). Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncology. 17(3). 430–9. 134 indexed citations
12.
Freiwald, Matthias, et al.. (2014). Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemotherapy and Pharmacology. 73(4). 759–770. 42 indexed citations
13.
Wind, Sven, et al.. (2013). Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours. Clinical Pharmacokinetics. 52(12). 1101–1109. 76 indexed citations
14.
15.
Schüler, Martin, Ahmad Awada, Philipp Harter, et al.. (2012). A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 134(3). 1149–1159. 71 indexed citations
16.
Taei, Afsaneh Asgari & Sven Wind. (2010). Role of NADPH Oxidase in the Endothelial Dysfunction and Oxidative Stress in Aorta of Aged Spontaneous Hypertensive Rats. SHILAP Revista de lepidopterología. 3 indexed citations
17.
Wind, Sven, Knut Beuerlein, Heimo Müller, et al.. (2010). Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. British Journal of Pharmacology. 161(4). 885–898. 205 indexed citations
18.
Wind, Sven, Eduardo Barbosa‐Sicard, Harald Schmidt, et al.. (2007). Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant. Hypertension. 51(2). 211–217. 637 indexed citations breakdown →
19.
Wind, Sven, et al.. (2005). Apocynin: Mother Nature's gift to combat oxidative stress. Pharmacognosy Magazine. 1(4). 136. 1 indexed citations
20.
Actor, Paul, et al.. (1962). Potentiation of Amphotericin B Activity Against Trypanosoma congolense in Mice. Experimental Biology and Medicine. 110(3). 409–412. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mukut Sharma Breakdown of academic impact, for papers by Xavier Durando Breakdown of academic impact, for papers by Tohru Yamamori Breakdown of academic impact, for papers by Ying Shen Breakdown of academic impact, for papers by Robert L. Wolfert Breakdown of academic impact, for papers by Han Si Breakdown of academic impact, for papers by Iain R. Hutcheson Breakdown of academic impact, for papers by Frank Weinberg Breakdown of academic impact, for papers by Ding Ai Breakdown of academic impact, for papers by Shixia Huang
Rankless by CCL
2026